(Q45208978)

English

Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor

scientific article published in October 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 December 2017

Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor (English)

1 reference

Europe PubMed Central

10 December 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

John J Thébault

1

1 reference

Europe PubMed Central

10 December 2017

Michel Guillaume

2

1 reference

Europe PubMed Central

10 December 2017

Ruth Levy

3

1 reference

Europe PubMed Central

10 December 2017

language of work or name

0 references

publication date

1 October 2004

1 reference

Europe PubMed Central

10 December 2017

Pharmacotherapy

1 reference

Europe PubMed Central

10 December 2017

24

1 reference

Europe PubMed Central

10 December 2017

10

1 reference

Europe PubMed Central

10 December 2017

1295-1305

1 reference

Europe PubMed Central

10 December 2017

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Multiple Forms of Human Brain Mitochondrial Monoamine Oxidase

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Comparative tolerability of the newer generation antiparkinsonian agents

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.14.1295.43156

21 January 2018

Identifiers

10.1592/PHCO.24.14.1295.43156

1 reference

Europe PubMed Central

10 December 2017

1 reference

Europe PubMed Central

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45208978&oldid=2143944070"